Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
MEIZHIGAO
834765
5
HIGO
872351
CN Stock MarketDetailed Quotes
688506 Sichuan Biokin Pharmaceutical
- 240.54
- +11.45+5.00%
Market Closed Apr 10 15:00 CST
96.46BMarket Cap26.02P/E (TTM)
247.00High230.92Low13.98KlotVolume240.00Open229.09Pre Close336.20MTurnover1.52%Turnover Ratio26.02P/E (Static)401.00MShares254.0052wk High24.82P/B22.15BFloat Cap113.8952wk Low274.91Limit Up92.07MShs Float254.00Historical High183.27Limit Down7.02%Amplitude28.75Historical Low--Dividend TTM240.52Avg Price5.95KlotAsk--Div YieldTTM100Lot Size6.14KlotBid
Sichuan Biokin Pharmaceutical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Money funds | 697.13%3.22B | 1,101.74%4.98B | 574.47%4.27B | 689.82%5.83B | -59.79%403.96M | 296.67%414.11M | 582.91%632.76M | --737.61M | 551.49%1B | --104.39M |
| Transactional financial assets | ---- | ---- | --1.63B | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Notes receivable and accounts receivable | 0.39%118.6M | -35.36%81.16M | -59.87%85.8M | -43.00%119.89M | -52.24%118.13M | -28.30%125.56M | 43.01%213.81M | --210.34M | 93.06%247.34M | --175.12M |
| -Notes receivable | -39.80%11.88M | -8.51%11.7M | 20.08%16.98M | 24.31%24.6M | 4.76%19.74M | -3.64%12.78M | 6.43%14.14M | --19.79M | -17.86%18.84M | --13.27M |
| -Accounts receivable | 8.46%106.72M | -38.41%69.46M | -65.53%68.82M | -49.99%95.29M | -56.94%98.39M | -30.32%112.78M | 46.58%199.67M | --190.55M | 117.25%228.5M | --161.85M |
| Other receivables (including interest and dividends) | 779.38%34.33M | 546.04%23.72M | 1,408.49%59.56M | 204.17%10.14M | -23.97%3.9M | -5.47%3.67M | 21.61%3.95M | --3.33M | 74.06%5.14M | --3.88M |
| -Accrued interest receivable | ---- | --14.35M | --48.59M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other receivable | 779.38%34.33M | ---- | 178.05%10.98M | ---- | -23.97%3.9M | ---- | 21.61%3.95M | ---- | 74.06%5.14M | --3.88M |
| Advance payment | 42.64%81.59M | 83.56%92.31M | 135.64%76.62M | 131.16%62.94M | 91.66%57.2M | 101.15%50.29M | 48.55%32.52M | --27.23M | 30.23%29.84M | --25M |
| Inventories | 15.10%162.19M | 20.98%164.88M | 15.96%154.18M | 25.73%152.89M | 39.06%140.91M | 52.06%136.29M | 44.92%132.96M | --121.6M | 23.08%101.33M | --89.63M |
| Receivable financing | 2.05%20.12M | 37.31%12.34M | -58.08%6.75M | -28.25%6.32M | -4.22%19.71M | -15.70%8.99M | 168.39%16.11M | --8.81M | 201.31%20.58M | --10.66M |
| Other current assets | 8,244.29%2.67B | 4,445.72%790.63M | 254.52%94.56M | 102.83%42.22M | 84.20%32M | 49.25%17.39M | 168.23%26.67M | --20.82M | -34.31%17.37M | --11.65M |
| Total current assets | 712.97%6.31B | 712.05%6.14B | 502.40%6.38B | 450.59%6.22B | -45.61%775.82M | 79.92%756.3M | 182.35%1.06B | --1.13B | 236.55%1.43B | --420.34M |
| Non Current assets | ||||||||||
| Investment real estate | -15.66%1.34M | -15.07%1.41M | -14.52%1.47M | -14.01%1.53M | -13.54%1.59M | -13.10%1.65M | -12.68%1.72M | --1.78M | -11.93%1.84M | --1.9M |
| Fixed assets | 11.46%498.93M | ---- | 52.04%495.48M | ---- | 31.25%447.63M | ---- | -7.84%325.89M | ---- | -8.52%341.04M | --347.93M |
| Constru in process | -56.36%35.51M | ---- | -75.30%26.02M | ---- | 21.06%81.37M | ---- | 87.40%105.34M | ---- | 269.80%67.21M | --61.92M |
| Intangible assets | -4.70%26.68M | -5.03%26.94M | -5.20%27.26M | -5.20%27.63M | -5.19%28M | -5.20%28.37M | -5.22%28.75M | --29.14M | -5.23%29.53M | --29.93M |
| Development expenditure | ---- | ---- | ---- | ---- | ---- | --6.83M | ---- | ---- | ---- | ---- |
| Long deferred expense | 912.96%18.4M | 46.19%3.8M | 58.86%3.55M | -20.51%2.12M | 1.38%1.82M | 52.78%2.6M | 44.88%2.24M | --2.67M | 54.15%1.79M | --1.7M |
| Deferred tax assets | 135.24%179.2M | 109.43%222.08M | 129.28%222.95M | -15.11%78.13M | -8.47%76.18M | 30.00%106.04M | 32.37%97.24M | --92.04M | 26.49%83.23M | --81.57M |
| Usufruct assets | 568.09%38.65M | 207.71%22.81M | 161.08%23.43M | -35.67%6.8M | -51.83%5.79M | -28.71%7.41M | -23.46%8.97M | --10.57M | -14.15%12.01M | --10.4M |
| Other non current assets | 354.98%31.45M | -36.30%17.73M | -79.22%7.4M | -85.10%5.92M | -75.69%6.91M | 6.10%27.84M | 79.08%35.61M | --39.71M | 26.67%28.43M | --26.24M |
| Total non current assets | 27.86%830.15M | 25.04%818.63M | 33.31%807.56M | 9.14%651.12M | 14.90%649.28M | 16.58%654.69M | 10.39%605.77M | --596.62M | 7.10%565.09M | --561.59M |
| Total assets | 400.83%7.14B | 393.28%6.96B | 331.69%7.19B | 298.02%6.87B | -28.44%1.43B | 43.69%1.41B | 80.20%1.66B | --1.73B | 109.30%1.99B | --981.93M |
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Short term loan | 116.45%595.5M | 287.28%650.71M | 276.74%670.73M | 177.42%375.45M | 77.34%275.12M | 14.77%168.02M | -9.28%178.04M | --135.34M | -3.78%155.13M | --146.39M |
| Notes payable and accounts payable | 46.87%498M | 30.36%387.11M | 24.41%362.79M | 45.02%333.05M | 71.99%339.07M | 96.40%296.96M | 156.02%291.6M | --229.65M | 171.72%197.14M | --151.2M |
| -Notes payable | 238.31%105.45M | 82.89%104.56M | 49.89%79.52M | -26.44%27.92M | 159.90%31.17M | 498.17%57.17M | 267.09%53.05M | --37.95M | --11.99M | --9.56M |
| -Accounts payable | 27.49%392.55M | 17.83%282.55M | 18.75%283.27M | 59.17%305.13M | 66.30%307.9M | 69.29%239.79M | 139.88%238.55M | --191.7M | 155.19%185.15M | --141.65M |
| Contract liabilities | 4,006.96%356.13M | 4,292.17%350.37M | 7,442.54%357.92M | 4,569.19%358.37M | -50.21%8.67M | 58.67%7.98M | -9.29%4.75M | --7.68M | 61.52%17.42M | --5.03M |
| Salaries payable | 79.44%79.48M | 55.80%53.6M | 31.74%38.06M | 21.00%26.88M | 10.74%44.29M | 11.86%34.4M | 20.40%28.89M | --22.22M | 44.99%40M | --30.76M |
| Taxs payable | 75.07%31.29M | 6,964.44%222.88M | 1,813.29%257.08M | 657.28%76.24M | -47.94%17.87M | -84.19%3.15M | -16.25%13.44M | --10.07M | 231.60%34.34M | --19.96M |
| Other payable (including interest and dividends) | 14.23%156.09M | -0.05%121.59M | -0.01%143.89M | -16.76%117.65M | -23.59%136.64M | -15.14%121.65M | 5.25%143.91M | --141.34M | 26.60%178.82M | --143.36M |
| -Other payable | 14.23%156.09M | ---- | -0.01%143.89M | ---- | -23.59%136.64M | ---- | 5.25%143.91M | ---- | 26.60%178.82M | --143.36M |
| Non current liabilities due within one year | 15.86%255.48M | 71.08%271.68M | 238.40%305.16M | 215.98%303.44M | 122.07%220.5M | 75.62%158.8M | 38.48%90.18M | --96.03M | 309.43%99.29M | --90.42M |
| Other current liabilities | -31.63%7.97M | -18.10%10.4M | 42.92%14.49M | 61.22%24.76M | -22.61%11.66M | 0.78%12.69M | -7.80%10.14M | --15.36M | -35.38%15.07M | --12.59M |
| Total current liabilities | 87.88%1.98B | 157.37%2.07B | 182.56%2.15B | 145.69%1.62B | 42.95%1.05B | 34.01%803.65M | 33.91%760.94M | --657.68M | 56.41%737.2M | --599.71M |
| Current liabilities | ||||||||||
| Long term account payable | ---- | ---- | ---- | ---- | -83.83%7.64M | ---- | -66.36%26.21M | ---- | 11.23%47.22M | --53.29M |
| Estimate liabilities | -13.12%9.73M | -14.38%10.23M | -34.00%9.36M | -19.62%11.33M | -20.35%11.19M | -9.55%11.94M | 5.00%14.18M | --14.1M | -11.12%14.05M | --13.21M |
| Deferred tax liabilities | --1.94M | ---- | ---- | ---- | ---- | --69.69K | --68.96K | ---- | --84.92K | ---- |
| Long term deferred income | 170.47%42.27M | -17.84%11.59M | -5.99%11.99M | 16.49%15.23M | 17.59%15.63M | 11.42%14.11M | -0.80%12.75M | --13.07M | -57.19%13.29M | --12.66M |
| Lease liabilities | 2,666.80%28.13M | 574.49%14.29M | 528.52%15.75M | -14.24%3.41M | -82.24%1.02M | -58.47%2.12M | -60.12%2.51M | --3.98M | -36.20%5.72M | --5.1M |
| Total non current liabilities | 479.55%1.27B | 240.45%649.93M | -31.15%206.99M | -67.24%99.88M | -31.51%219.39M | -34.22%190.9M | 87.25%300.65M | --304.84M | 116.03%320.33M | --290.23M |
| Total liabilities | 155.37%3.25B | 173.31%2.72B | 122.04%2.36B | 78.25%1.72B | 20.40%1.27B | 11.75%994.56M | 45.66%1.06B | --962.52M | 70.68%1.06B | --889.95M |
| Shareholders equity | ||||||||||
| Paid-in capital | 0.00%401M | 0.00%401M | 0.00%401M | 0.00%401M | 0.00%401M | 11.11%401M | 11.11%401M | --401M | 11.11%401M | --360.9M |
| Capital reserve funds | 3.16%885.84M | 1.07%867.76M | 0.30%861.2M | 0.02%858.69M | 0.02%858.69M | 5,935.84%858.6M | 5,946.08%858.6M | --858.55M | 5,960.23%858.55M | --14.22M |
| Surplus reserve funds | 0.00%13.54M | 0.00%13.54M | 0.00%13.54M | 0.00%13.54M | 0.00%13.54M | 0.00%13.54M | 0.00%13.54M | --13.54M | 0.00%13.54M | --13.54M |
| Retained profit | 330.30%2.59B | 443.36%2.94B | 628.70%3.54B | 863.21%3.88B | -228.23%-1.12B | -183.50%-857.09M | -239.89%-670.3M | ---508.73M | -474.63%-341.98M | ---302.32M |
| Other composite income | -53.03%528.8K | 4,245.48%16.72M | 6,567.11%8.98M | 37.78%-321.01K | -59.69%1.13M | -93.19%384.68K | -96.14%134.72K | ---515.95K | 1.24%2.79M | --5.64M |
| Shareholders equity without minority interests | 2,458.66%3.89B | 918.64%4.24B | 700.80%4.83B | 574.96%5.16B | -83.74%151.87M | 352.71%416.43M | 209.35%602.97M | --763.84M | 181.42%933.89M | --91.99M |
| Total shareholder equity | 2,458.66%3.89B | 918.64%4.24B | 700.80%4.83B | 574.96%5.16B | -83.74%151.87M | 352.71%416.43M | 209.35%602.97M | --763.84M | 181.42%933.89M | --91.99M |
| Total liabilityies and equity | 400.83%7.14B | 393.28%6.96B | 331.69%7.19B | 298.02%6.87B | -28.44%1.43B | 43.69%1.41B | 80.20%1.66B | --1.73B | 109.30%1.99B | --981.93M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- | -- |
| Auditor | -- | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.